Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?

Autor(es)

Viel, Tania ^[1] ; Chinta, Shankar ^{[2, 3]} ; Rane, Anand ^[2] ; Chamoli, Manish ^[2] ; Buck, Hudson ^{[4, 5]} ; Andersen, Julie ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Arts Sci & Humanities, Lab Neuropharmacol Aging, Sao Paulo, SP - Brazil

^[2] Buck Inst Res Aging, Novato, CA 94945 - USA

^[3] Touro Univ Calif, Vallejo, CA 94592 - USA

^[4] Santa Casa Sao Paulo Sch Med Sci, Dept Physiol Sci, Sao Paulo, SP - Brazil

^[5] Santa Casa Sao Paulo Sch Med Sci, Dept Physiol Sci, Sao Paulo, SP, Brazil.Viel, Tania, Univ Sao Paulo, Sch Arts Sci & Humanities, Lab Neuropharmacol Aging, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: AGING-US; v. 12, n. 11, p. 10035-10040, JUN 15 2020.
• Citações Web of Science: 0

Resumo

Cell senescence is a process that causes growth arrest and the release of a senescence associated secretory phenotype (SASP), characterized by secretion of chemokines, cytokines, cell growth factors and metalloproteases, leading to a tissue condition that may precipitate cancers and neurodegenerative processes. With the recent pandemic of coronavirus, senolytic drugs are being considered as possible therapeutic tools to reduce the virulence of SARS-CoV-2. In the last few years, our research group showed that lithium carbonate at microdose levels was able to stabilize memory and change neuropathological characteristics of Alzheimer's disease (AD). In the present work, we present evidence that low-dose lithium can reduce the SASP of human iPSCs-derived astrocytes following acute treatment, suggesting that microdose lithium could protect cells from senescence and development of aging-related conditions. With the present findings, a perspective of the potential use of low-dose lithium in old patients from the ``high risk group{''} for COVID-19 (with hypertension, diabetes and chronic obstructive pulmonary disease) is presented. (AU)

• Processo FAPESP: 18/05288-6 - Um enfoque racional para aprimorar a investigação biotecnológica do lítio em microdose usando células-tronco pluripotentes induzidas
• Beneficiário: Tânia Araújo Viel
• Modalidade de apoio: Bolsas no Exterior - Pesquisa
• Processo FAPESP: 19/03486-8 - Estudo da modulação de vias de sobrevivência celular pelo Receptor B2 da bradicinina e seu impacto na neuroinflamação, em cultura organotípica de hipocampo de camundongo transgênico para a Doença de Alzheimer
• Beneficiário: Hudson de Sousa Buck
• Modalidade de apoio: Auxílio à Pesquisa - Regular